Tags

Type your tag names separated by a space and hit enter

Fibroblast growth factor 23 and the future of phosphorus management.
Curr Opin Nephrol Hypertens. 2009 Nov; 18(6):463-8.CO

Abstract

PURPOSE OF REVIEW

To present emerging data on the role of fibroblast growth factor 23 (FGF23) in mineral metabolism and adverse outcomes in chronic kidney disease (CKD).

RECENT FINDINGS

FGF23 regulates phosphorus and vitamin D metabolism. Its levels increase progressively beginning in early CKD, presumably as a physiological adaptation to maintain normal serum phosphate levels or normal phosphorus balance. FGF23 promotes phosphaturia and decreases production of calcitriol. Recent studies suggest that increased FGF23 is associated with mortality, left ventricular hypertrophy, endothelial dysfunction and progression of CKD. These results were consistently independent of serum phosphate levels.

SUMMARY

FGF23 is emerging as a novel and exciting biomarker that may help identify which CKD patients might benefit most from aggressive management of disordered phosphorus metabolism. Future studies should determine whether increased FGF23 levels exert direct end-organ toxicity, such as in the heart, vessels and kidneys.

Authors+Show Affiliations

Division of Nephrology and Hypertension, Department of Medicine, University of Miami, Miller School of Medicine, Miami, Florida 33136, USA. mwolf2@med.miami.edu

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

19770756

Citation

Wolf, Myles. "Fibroblast Growth Factor 23 and the Future of Phosphorus Management." Current Opinion in Nephrology and Hypertension, vol. 18, no. 6, 2009, pp. 463-8.
Wolf M. Fibroblast growth factor 23 and the future of phosphorus management. Curr Opin Nephrol Hypertens. 2009;18(6):463-8.
Wolf, M. (2009). Fibroblast growth factor 23 and the future of phosphorus management. Current Opinion in Nephrology and Hypertension, 18(6), 463-8. https://doi.org/10.1097/MNH.0b013e328331a8c8
Wolf M. Fibroblast Growth Factor 23 and the Future of Phosphorus Management. Curr Opin Nephrol Hypertens. 2009;18(6):463-8. PubMed PMID: 19770756.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fibroblast growth factor 23 and the future of phosphorus management. A1 - Wolf,Myles, PY - 2009/9/23/entrez PY - 2009/9/23/pubmed PY - 2009/12/25/medline SP - 463 EP - 8 JF - Current opinion in nephrology and hypertension JO - Curr Opin Nephrol Hypertens VL - 18 IS - 6 N2 - PURPOSE OF REVIEW: To present emerging data on the role of fibroblast growth factor 23 (FGF23) in mineral metabolism and adverse outcomes in chronic kidney disease (CKD). RECENT FINDINGS: FGF23 regulates phosphorus and vitamin D metabolism. Its levels increase progressively beginning in early CKD, presumably as a physiological adaptation to maintain normal serum phosphate levels or normal phosphorus balance. FGF23 promotes phosphaturia and decreases production of calcitriol. Recent studies suggest that increased FGF23 is associated with mortality, left ventricular hypertrophy, endothelial dysfunction and progression of CKD. These results were consistently independent of serum phosphate levels. SUMMARY: FGF23 is emerging as a novel and exciting biomarker that may help identify which CKD patients might benefit most from aggressive management of disordered phosphorus metabolism. Future studies should determine whether increased FGF23 levels exert direct end-organ toxicity, such as in the heart, vessels and kidneys. SN - 1473-6543 UR - https://www.unboundmedicine.com/medline/citation/19770756/Fibroblast_growth_factor_23_and_the_future_of_phosphorus_management_ L2 - https://doi.org/10.1097/MNH.0b013e328331a8c8 DB - PRIME DP - Unbound Medicine ER -